Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
Open Access
- 20 June 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Abstract
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating the identification of additional CAR-T targets. Here, we show that FcRH5 is expressed on multiple myeloma cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells elicited antigen-specific activation, cytokine secretion and cytotoxicity against MM cells. Moreover, FcRH5 CAR-T cells exhibited robust tumoricidal efficacy in murine xenograft models, including one deficient in BCMA expression. We also show that different forms of soluble FcRH5 can interfere with the efficacy of FcRH5 CAR-T cells. Lastly, FcRH5/BCMA-bispecific CAR-T cells efficiently recognized MM cells expressing FcRH5 and/or BCMA and displayed improved efficacy, compared with mono-specific CAR-T cells in vivo. These findings suggest that targeting FcRH5 with CAR-T cells may represent a promising therapeutic avenue for MM.Keywords
This publication has 47 references indexed in Scilit:
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myelomaBritish Journal of Haematology, 2016
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma CellsClinical Cancer Research, 2014
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple MyelomaClinical Cancer Research, 2013
- FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple MyelomaMolecular Cancer Therapeutics, 2012
- Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometryJournal of Translational Medicine, 2012
- Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaLeukemia, 2006
- Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemiaInternational Immunology, 2006
- Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human seraClinical Chemistry and Laboratory Medicine (CCLM), 2006
- Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal AntibodiesClinical Cancer Research, 2005
- Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple MyelomaThe American Journal of Pathology, 2004